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Introduction. We aimed to analyze and compare the most up-to-date breast and lung cancer mortality rates in European 
women aged 45–74.
Material and methods. The data on breast and lung cancer mortality in 1960–2017 were obtained from the World Health 
Organization Mortality Data Base and Eurostat. To determine the mortality trends and generate annual percent change, 
with 95% confidence intervals, joinpoint regression was applied. 
Results. In most European Union (EU) member states (15 out of 28), lung cancer mortality was higher than breast cancer 
mortality, with either increasing or stable lung cancer mortality rates. In four other EU countries, breast and lung cancer 
mortality rates in the last reported year were almost equal or equal.
Conclusions. Lung cancer is becoming the leading cause of cancer deaths among European women. There is a need for 
ensuring women-targeted smoking cessation services to decrease tobacco-attributable lung cancer mortality.
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Introduction
Breast cancer is the most prevalent female neoplasm worl-
dwide. According to the International Agency for Research on 
Cancer (IARC), in 2018, globally, 2,261,419 women were dia-
gnosed with breast cancer. Moreover, breast cancer is a leading 
cause of cancer deaths among women (684,996 deceases in 
2018). According to the same global cancer statistics, lung 
cancer is the third-most-common female neoplasm and the 
second-most-common cause of female cancer deaths globally, 
with the number of incident cases at 770,828 and the number 
of deaths at 607,465  in 2018 [1]. In the European Union (EU; 
state of 2018 with 28 EU member states), breast cancer is still 
the most prevalent female neoplasm, however, lung cancer is 
now the leading cause of female cancer deaths [2].
While a systematic understanding of breast cancer risk 
factors is still unsatisfactory, it is already known that about 
70–80% of female lung cancer cases are associated exclusive-
ly to tobacco smoking [3, 4]. Hence, cancer mortality trends 
are affected by changes in European tobacco consumption 
patterns. At the end of the 20th century, tobacco-related 
mortality decreased among men, and was stable or increased 
among women [5]. This phenomenon is evident in lung 
cancer, considered a good proxy for smoking prevalence 
estimations. 
Although mechanisms underpinning cancer prevalence 
and mortality rates are not fully understood, their changes 
can be a valuable indicator for policymakers and stakehol-
ders, enabling more tailored and efficient actions aimed at 
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decreasing tobacco consumption in the EU and its suitable 
member states. This study aimed to analyze and compare the 
most recent female breast and lung cancer mortality rates in 
31 European countries.
Material and methods
The presented analysis is an update of the data published in the 
article by Sulkowska et al. in Nowotwory. Journal of Oncology 
2015; 65 (5): 395–403, entitled Lung cancer, the leading cause 
of cancer deaths among women in Europe [5]. We followed pre-
viously applied methodology (including the same age group: 
45–74 years old) to enable comparability of the data.
Source of the data
The analyzed data were obtained in a hybrid manner. First, 
we obtained data from the World Health Organization (WHO) 
Mortality Data Base (MDB) (data available as of 15th December 
2019). The MDB contains the number of deaths by country, 
year, sex, age group, and cause of death. The cause of death is 
coded according to the International Classification of Diseases 
(ICD). We identified all female deaths due to breast and lung 
cancer registered in the MDB since 1960 in 28 EU member 
states and three non-member states, namely Norway, Russia, 
and Switzerland. The included diagnosis codes encompassed 
lung cancer (162–163 – ICD 7th revision; 162 – ICD 8th and 
9th revisions; and C33 and C34 – ICD 10th revision) and breast 
cancer (170 – 7th revision; 174 – 8th and 9th revisions; and C50 – 
10th revision). In cases where the data for additional (following) 
years were available in Eurostat, these were also included in our 
analysis (detailed data sources, by country, by year in table I). 
The mid-year population estimates were obtained from WHO 
MDB and Eurostat.
Statistical analysis
Crude annual mortality rates were defined as the number of 
new deaths per 100,000 person-years. In the denominator, we 
applied the mid-year population, defined as the population’s 
size on the 31st of June. In all calculations, both the numerator 
and denominator came from the same data source, WHO MDB 
or Eurostat. To enable a comparison with other populations, 
we performed direct age-standardization for the Segi’s World 
Standard Population [6]. For Luxembourg and Malta, the mor-
tality rates were calculated as three-year moving averages 
(deploying the preceding and following year).
To determine mortality trends and to generate the annual 
percent change (APC), with 95% confidence intervals (CI), jo-
inpoint regression was applied [7]. The best-fitting model was 
selected with permutations tests, with an overall significance 
level at 0.05 and the number of randomly permutated data 
sets for permutation set at 4499. Rates were considered to 
decrease if APC < 0 and 95% CI does not contain zero, and 
to increase if APC > 0 and 95% CI do not contain zero; other-
wise, rates were considered stable.
Joinpoint analysis was performed using the Joinpoint 
Regression Program (version 4.3.1.0, National Cancer Institute, 
Bethesda, MD, USA).
Compliance with ethical standards
According to the WHO and Eurostat policies, the analyzed 
data can be freely used for scientific purposes. This study was 
conducted according to the Strengthening the Reporting 
of Observational Studies in Epidemiology (STROBE) guide-
lines [8].
Results
Breast and lung cancer mortality rates in 1960–2017, analyzed 
by EU member states, manifested four different patterns: 
• Group 1 – higher mortality from lung cancer than from bre-
ast cancer with increasing mortality rates of lung cancer; 
• Group 2 – higher mortality from lung cancer than from 
breast cancer with stable or decreasing lung cancer mor-
tality rates; 
• Group 3 – almost equal or equal breast and lung cancer 
mortality rates in the last reported year; 
• Group 4 – other EU countries (tab. I).
Non-EU countries were analyzed separately, as Group 5.
In the vast majority of countries in group 1, lung and breast 
cancer mortality rates intersected around 2010. In Poland the 
intersection occurred in 2004, and in Spain in 2016 (fig. 1 A). 
In Austria, Croatia, Germany, and Slovenia, the increase in lung 
cancer mortality rates was constant. In Poland, a very short pe-
riod of trend stabilization was observed between 1968–1972, 
and in Luxembourg, lung cancer mortality rates decreased 
between 1971–1974. In Czechia, the trend began stabilizing 
in 2000. In Spain, in 1990, after years of a plateau, lung cancer 
mortality rates started increasing.
In group 2, time of the lung and breast mortality trends in-
tersection varied widely, e.g., in Denmark it took place in 1991, 
in Sweden in 2001, and in Ireland in 2012 (fig. 1 B). Lung cancer 
mortality rates were sharply dropping in Belgium, Denmark, 
Sweden, and the United Kingdom. In Hungary, Ireland, and 
the Netherlands, the decrease was more gradual. The onset of 
decreasing rates for lung cancer mortality ranged from 1980 
in Ireland to 2015 in Belgium.
In group 3, the breast and lung cancer mortality rates were 
almost equal or equal (fig. 1 C). In all countries in the group, 
lung cancer mortality increased; however, only in Italy was the 
increase constant. The trend plateaued in Finland and France 
in 1962–1974 and in 1960–1977, respectively. 
In every country in group 4, lung cancer mortality has 
always been lower than breast cancer mortality (fig. 1 D). Ho-
wever, in some countries (Bulgaria, Cyprus, Estonia, Lithuania, 
Malta, Portugal, and Romania), the breast cancer mortality 
rate has been decreasing substantially and/or the lung cancer 
mortality rate has been sharply increasing, which might point 

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 1. A. Breast and lung cancer mortality rates among women aged 45–74-years-old. Group 1 – EU countries with higher mortality from lung cancer 
than from breast cancer with increasing lung cancer mortality rates
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Figure 1. B. Breast and lung cancer mortality rates among women aged 45–74-years-old. Group 2 – EU countries with higher mortality from lung cancer 
than from breast cancer with stable or decreasing lung cancer mortality rates
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Figure 1. C. Breast and lung cancer mortality rates among women aged 45–74-years-old. Group 3 – EU countries with almost equal or equal breast and 
lung cancer mortality rates in the last reported year
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Figure 1. D. Breast and lung cancer mortality rates among women aged 45–74-years-old. Group 4 – other EU countries
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Group 5 represents three non-EU countries (fig. 1 E). 
In  Norway and Switzerland the rates intersected in 1998 
and 2012, respectively. In Russia, such a phenomenon has 
never occurred. 
Discussion
The presented analysis depicts a substantial increase in female 
lung cancer mortality across the vast majority of European 
countries (tab. II). In comparison with our previous analysis on 
female lung and breast cancer mortality in the EU [5] (the last 
reported year was 2010), we noticed progressive cancer mor-
tality changes. Previously we had forecasted further increases 
in lung cancer mortality and the intersection of both analyzed 
trends for 12 EU countries. This forecast proved to be true 
for Belgium, Croatia, Spain, Ireland, Germany, and Slovenia, 
in our current analysis. However, in Finland, France, Greece, 
and Italy, the trends have not intersected yet. Contrary to our 
earlier predictions, the current analysis shows that in Estonia 
and Slovakia breast cancer mortality is still higher than lung 
cancer mortality.
Considering the most up-to-date data on tobacco use, we 
know that at present in the EU about 47 million women currently 
smoke. Moreover, the advanced stage of tobacco epidemic was 
observed in 12 UE member states, where smoking prevalence 
among women is higher than 15% [9]. According to the Institute 
for Health Metrics and Evaluation (IHME), an exceptionally high 
smoking-attributable disease burden is observed in Bulgaria, 
Croatia, Greece, Hungary, and Poland, with the disability-adju-
sted life years index ranging between 17.5% and 20% [10]. Trends 
reported in our analysis are following the IHME data. Noteworthy, 
in Poland and Croatia, the increase is very sharp, and Hungary is 
characterized by the highest lung cancer mortality rate among 
all 31 analyzed countries (>100 per 100,000).
The presented analysis implies that greater efforts are 
needed to ensure a decline in lung cancer mortality rates. 
Several possible courses of action are mainly related to more 
restrictive anti-tobacco policies. Raising the excise tax for to-
bacco products is one of the most effective tools to achieve 
this goal [11], particularly among women who are more re-
sponsive to such measures than men [12]. Another solution is 
banning menthol and slim cigarettes, perceived as being more 
feminine tobacco products, targeted primarily at this group 
of users [13, 14]. Some of these solutions have already been 
introduced under the Tobacco Products Directive (2014/40/
EU) [15]. However, the decline in lung cancer mortality ob-
served in our analysis should not yet be connected with the 
enforcement of this particular law, since it has been in force 
too short to impact the mortality statistics. Notwithstanding, 
effective implementation of the Directive should be a priority 
for European policymakers, since it may further reduce lung 
cancer mortality among EU women. 
The strength of the analysis is in the completeness of 
the analyzed cause-of-death data, which was close to 100%, 
except for Cyprus, where it was 68% [16]. The most important 
limitation of the study results from the possible cross-natio-
nal differences in coding practices, particularly in codes for 
ill-defined and unknown causes. This should be taken into 
account when comparing mortality rates for specific causes 
E
Figure 1. E. Breast and lung cancer mortality rates among women aged 45–74-years-old. Group 5 – non-EU countries
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across countries. However, since we assessed time trends of 
mortality rates within the countries in this study, the presented 
results’ generalizability should not be limited. 
Conclusions
In many European countries during the last decades, lung cancer 
has become the leading cause of cancer deaths among women. 
Ensuring the implementation of gender-tailored evidence-ba-
sed smoking cessation services and primary smoking prevention 
actions should be a priority for European healthcare policyma-
kers to decrease tobacco-attributable lung cancer mortality.
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